RxDoctor Payments Data

Gennaro Giustino, MD

Cardiovascular Disease · Morristown, NJNPI 1174985113

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (52.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Edwards Lifesciences accounts for 68.1% of it on its own, with 29 other manufacturers making up the rest. 2025 is the largest year on record at $99,136, more than ten times the $3,719 reported in 2019. Among cardiovascular disease clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$134,638in general payments, 2019–2025

Across 578 payments — averaging $232.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$92K
  • Medtronic$26K
  • E.r. Squibb & Sons, L.L.C.$4K
  • Abbott$2K
  • Shockwave Medical, Inc$2K
  • AstraZeneca$1K
  • plus $7K from 24 others
$32,167in research payments, 2019–2025

Across 2 payments — averaging $16,084 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$32K

What the payments were for

  • Consulting fees$70,95753%
  • Speaking & faculty fees$1,5001%
  • Grants$13,00010%
  • Travel & lodging$25,85519%
  • Food & beverage$23,32517%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$134,638 in reported general payments places this provider in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$46,275
Medicare patients
90
Services billed
253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Morristown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →